These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 29175009

  • 1. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
    Ghazal K, Stenard F, Dahlqvist G, Barjon C, Aoudjehane L, Scatton O, Conti F.
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A, Wilde B, Wang J, Tebbe B, Jing L, Wang X, Jian F, Zhu J, Dolff S, Kribben A, Hoyer PF, Witzke O.
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F, Christians U, Smith L, Wellen JR, Kaplan B.
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [Abstract] [Full Text] [Related]

  • 7. Oscillatory mTOR inhibition and Treg increase in kidney transplantation.
    Sabbatini M, Ruggiero G, Palatucci AT, Rubino V, Federico S, Giovazzino A, Apicella L, Santopaolo M, Matarese G, Galgani M, Terrazzano G.
    Clin Exp Immunol; 2015 Nov; 182(2):230-40. PubMed ID: 26077103
    [Abstract] [Full Text] [Related]

  • 8. Influence of everolimus-based treatment on circulating regulatory T cells after liver transplantation: Comparative study with tacrolimus-based therapy.
    Barjon C, Dahlqvist G, Ghazal K, Saliba F, Durand F, Duvoux C, Aoudjehane L, Conti F.
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101559. PubMed ID: 33191181
    [Abstract] [Full Text] [Related]

  • 9. mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation.
    Gedaly R, De Stefano F, Turcios L, Hill M, Hidalgo G, Mitov MI, Alstott MC, Butterfield DA, Mitchell HC, Hart J, Al-Attar A, Jennings CD, Marti F.
    Transplantation; 2019 Apr; 103(4):705-715. PubMed ID: 30451741
    [Abstract] [Full Text] [Related]

  • 10. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ, Felipe CR, Tedesco-Silva H, Osmar Medina-Pestana J.
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [Abstract] [Full Text] [Related]

  • 11. Differential regulation of Tregs and Th17/Th1 cells by a sirolimus-based regimen might be dependent on STAT-signaling in renal transplant recipients.
    Li Y, Shi Y, Liao Y, Yan L, Zhang Q, Wang L.
    Int Immunopharmacol; 2015 Sep; 28(1):435-43. PubMed ID: 26186486
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients.
    Fourtounas C, Dousdampanis P, Sakellaraki P, Rodi M, Georgakopoulos T, Vlachojannis JG, Mouzaki A.
    Am J Nephrol; 2010 Sep; 32(1):1-9. PubMed ID: 20484893
    [Abstract] [Full Text] [Related]

  • 14. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients.
    Levitsky J, Mathew JM, Abecassis M, Tambur A, Leventhal J, Chandrasekaran D, Herrera N, Al-Saden P, Gallon L, Abdul-Nabi A, Yang GY, Kurian SM, Salomon DR, Miller J.
    Hepatology; 2013 Jan; 57(1):239-48. PubMed ID: 22234876
    [Abstract] [Full Text] [Related]

  • 15. Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses.
    Levitsky J, Miller J, Huang X, Gallon L, Leventhal JR, Mathew JM.
    PLoS One; 2016 Jan; 11(6):e0156535. PubMed ID: 27275747
    [Abstract] [Full Text] [Related]

  • 16. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G, Felipe CR, Cristelli MP, Mansur Siliano J, Viana L, Ferreira Brigido AN, Stopa Martins SB, de Castro Lima Santos DW, Aguiar WF, Tedesco-Silva Junior H, Medina-Pestana JO.
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the impact of conventional immunosuppressant on the establishment of murine transplantation tolerance - an experimental study.
    Katsumata H, Miyairi S, Ikemiyagi M, Hirai T, Fukuda H, Kanzawa T, Ishii R, Saiga K, Ishii Y, Omoto K, Okumi M, Yokoo T, Tanabe K.
    Transpl Int; 2019 Apr; 32(4):443-453. PubMed ID: 30561097
    [Abstract] [Full Text] [Related]

  • 18. Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors.
    Mittal SK, Sharma RK, Gupta A, Naik S.
    Transplantation; 2009 Aug 15; 88(3):435-41. PubMed ID: 19667950
    [Abstract] [Full Text] [Related]

  • 19. Comparing the Effects of the mTOR Inhibitors Azithromycin and Rapamycin on In Vitro Expanded Regulatory T Cells.
    Bergström M, Müller M, Karlsson M, Scholz H, Vethe NT, Korsgren O.
    Cell Transplant; 2019 Dec 15; 28(12):1603-1613. PubMed ID: 31512504
    [Abstract] [Full Text] [Related]

  • 20. Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.
    Huijts CM, Santegoets SJ, Quiles Del Rey M, de Haas RR, Verheul HM, de Gruijl TD, van der Vliet HJ.
    Clin Immunol; 2016 Jul 15; 168():47-54. PubMed ID: 27189717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.